Percutaneous Coronary Intervention Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Left Ventricular Assist Device Recipients with a History of Cardiovascular Disease or Cardiothoracic Surgery Have Increased Mortality
Purpose: Right ventricular failure (RVF) is a major complication following left ventricular assist device (LVAD) placement and can significantly increase mortality. The identification of preoperative risk factors could help delineate the risk for RVF in LVAD recipients. While early RVF is well established, the risk factors for late RVF remain are not well established. Our goal was to evaluate the prevalence of late RVF in LVAD patients with a history of coronary artery disease (CAD) and prior cardiac surgery (coronary artery bypass grafting [CABG] or percutaneous coronary intervention). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S.S. Scott, S. Smith Source Type: research

Clinical Outcomes of Renal Transplant Recipients Undergoing Percutaneous Coronary Intervention
Clinical outcomes of patients with renal transplant (RT) undergoing percutaneous coronary intervention (PCI) remain poorly elucidated. (Source: Heart, Lung and Circulation)
Source: Heart, Lung and Circulation - April 1, 2024 Category: Cardiology Authors: Wayne C. Zheng, Nicole Evans, Diem Dinh, Jason E. Bloom, Angela L. Brennan, Jocasta Ball, Jeffrey Lefkovits, James A. Shaw, Christopher M. Reid, William Chan, Dion Stub Tags: Original Article Source Type: research

Risk Prediction and Standardisation of Cardiogenic Shock Care
Cardiogenic shock (CS), specifically complicating acute myocardial infarction (AMI), continues to be associated with high morbidity and mortality despite advances in pharmacotherapy, percutaneous coronary intervention (PCI) techniques, and temporary mechanical circulatory support (MCS) device technology [1]. Poor in-hospital and long-term outcomes are largely attributable to heterogeneity in the presentation, aetiology, severity, and clinical assessment of CS, which continues to be challenging [2]. (Source: Heart, Lung and Circulation)
Source: Heart, Lung and Circulation - April 1, 2024 Category: Cardiology Authors: Saraschandra Vallabhajosyula, Vinayak Nagaraja Tags: Editorial Source Type: research

Evaluating biomarkers for contrast-induced nephropathy following coronary interventions: an umbrella review on meta-analyses
ConclusionNGAL demonstrated superior diagnostic performance, exhibiting the highest AUC, positive likelihood ratio, and diagnostic odds ratio among biomarkers for CIN, followed by cystatin-C, and uKIM-1. These findings underscore the potential clinical utility of NGAL, cystatin-C and uKIM-1 in predicting and assessing CIN.Graphical Abstract (Source: European Journal of Medical Research)
Source: European Journal of Medical Research - April 1, 2024 Category: Research Source Type: research

Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome
This study included ACS patients who underwent percutaneous coronary intervention and, at discharge between January 1, 2018 and December 31, 2020, were prescribed with low-dose prasugrel plus aspirin or standard-dose ticagrelor plus aspirin. Stabilized inve rse probability of treatment weighting was used to balance the covariates across these two groups. The primary effectiveness outcome was a composite of acute myocardial infarction, ischemic stroke, and cardiovascular death; the secondary effectiveness outcome was each of the individual components of the primary outcome, transient ischemic attack, and repeat revasculariz...
Source: Journal of Thrombosis and Thrombolysis - March 31, 2024 Category: Hematology Source Type: research

Relation of plasma neuropeptide-Y with myocardial function and infarct severity in acute ST-elevation myocardial infarction
CONCLUSION: High plasma levels of NPY, measured 24h after STEMI, were independently associated with lower LVEF, decreased GLS, larger IS as well as presence of MVO, indicating plasma NPY as a novel clinical risk marker post STEMI.PMID:38555253 | DOI:10.1016/j.ejim.2024.03.027 (Source: European Journal of Internal Medicine)
Source: European Journal of Internal Medicine - March 30, 2024 Category: Internal Medicine Authors: Christina Tiller Martin Reindl Magdalena Holzknecht Ivan Lechner Felix Troger Fritz Oberhollenzer Sebastian von der Emde Thomas Kremser Agnes Mayr Axel Bauer Bernhard Metzler Sebastian J Reinstadler Source Type: research

Development and validation of a prognostic model for predicting post-discharge mortality risk in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI)
Accurately predicting post-discharge mortality risk in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) remains a complex and critic... (Source: Journal of Cardiothoracic Surgery)
Source: Journal of Cardiothoracic Surgery - March 30, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Lingling Zhang, Zhican Liu, Yunlong Zhu, Mingxin Wu, Haobo Huang, Wenbin Yang, Ke Peng and Jianping Zeng Tags: Research Source Type: research

Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
ConclusionAmong adults who underwent first-ever PCI for ACS, ticagrelor use in the DAPT was associated with a lower risk of MOF compared with clopidogrel. Our results support the use of ticagrelor in the DAPT from the perspective of bone health. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 29, 2024 Category: Endocrinology Source Type: research

Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention
CONCLUSIONS: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination...
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Li Ye Sijia Tu Source Type: research